Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Yahoo12 hours agoREGN
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron Pharmaceuticals has a market
Benzinga2 days agoREGN
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.
Yahoo2 days agoREGN
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.
SeekingAlpha4 days agoREGN
Non-Melanoma Skin Cancer Market: Focus on Disease Indication, Treatment Type, Country and Region, 2025-2035
The global non-melanoma skin cancer (NMSC) market is growing as basal cell carcinoma and squamous cell carcinoma rates rise due to UV exposure and aging populations. Advanced diagnostics, AI, targeted therapies, superficial radiation therapy and electronic brachytherapy are improving early detection and outcomes. North America leads the market, followed by Europe, while Asia-Pacific is expanding rapidly. Key players include Amgen, Regeneron, Almirall and Boehringer Ingelheim. FDA-approved Libtay
Yahoo4 days agoREGN
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View
Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...
Yahoo5 days agoREGN
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP
Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...
Yahoo5 days agoREGN
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
Benzinga7 days agoREGN
Corvus Pharmaceuticals: Steady As She Goes With Strong Footing In Atopic Dermatitis Treatment
Corvus Pharmaceuticals has delivered strong soquelitinib data in atopic dermatitis, driving a significant market rally and a robust cash raise. Learn more about CRVS stock here.
SeekingAlpha8 days agoREGN
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron Pharmaceuticals has a market
Benzinga10 days agoREGN
Oil Shipper Hits New High; Three Stocks Also Near Pivots
Oil transportation stock Frontline is at a new high in Friday's stock market. Advantest, Regeneron Pharma and Magna International are also at highs.
Yahoo13 days agoREGN
How Moderna’s Historic Short Squeeze Upended the AI Chip Trade
Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.
Yahoo14 days agoREGN
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.
Yahoo15 days agoREGN
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech stock outlook: Hold rating after missed H1 2026 earnings and FDA CRLs; biosimilar pipeline targets Q4 2026. Click for this ALVO update.
SeekingAlpha15 days agoREGN
Regeneron to challenge Ipsen as FDA clears bone disease drug
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
Yahoo15 days agoREGN
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.
Benzinga15 days agoREGN
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.
Benzinga15 days agoREGN
Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...
Yahoo15 days agoREGN
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)
Benzinga16 days agoREGN
AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?
Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.
SeekingAlpha16 days agoREGN
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.
Benzinga17 days agoREGN
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Nektar Therapeutics earns a Strong Buy on REZPEG Phase 3 AD/AA upside, $1.02B cash runway to 2028, and big market opportunity. Click for this NKTR update.
SeekingAlpha21 days agoREGN
If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron Pharmaceuticals has a market
Benzinga21 days agoREGN
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, expanding application of company's proprietary HeliconTM platform; received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties Ended the second quarter with a strong fina
Yahoo22 days agoREGN